Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SASPject AP6.2
- Development stage
- Preclinical
- Lead developer
- SASPiPhi
- Modality
- Gene Therapies
01
Overview
SASPject AP6.2 is an engineered, non-lytic bacteriophage therapeutic in preclinical development (Lead Optimisation) by SASPiPhi for the treatment of infections caused by *Acinetobacter baumannii*. Developed using the proprietary SASPject platform (originally created by Phico Therapeutics), the drug consists of a modified bacteriophage designed to act as a targeted nano-delivery vehicle. Upon binding to and infecting *A. baumannii*, the phage injects a gene encoding a small acid-soluble spore protein (SASP). Intracellular expression of SASP leads to its binding to bacterial DNA, shifting the DNA conformation from B-like to A-like. This non-sequence-specific binding inactivates the bacterial DNA, halting replication and transcription, and rapidly killing the pathogen without lysing the cell or promoting resistance.
02
Targets
DNA
Beyond the preview
Go deeper on SASPject AP6.2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SASPject AP6.2.